Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA gyrase is a unique and essential bacterial enzyme classified as a type II topoisomerase. It catalyzes the ATP-dependent introduction of negative supercoils into double-stranded, closed-circular DNA, which is critical for maintaining DNA topology during processes such as replication, transcription, and recombination. Unlike other topoisomerases, DNA gyrase is the only known enzyme capable of actively introducing negative supercoils into DNA. It is a heterotetramer composed of two GyrA and two GyrB subunits (A₂B₂). The GyrA subunit contains the active site tyrosine responsible for cleaving and rejoining the DNA strands, while the GyrB subunit harbors the ATP-binding and hydrolysis sites necessary for energy transduction during catalysis. DNA gyrase is an established antibacterial drug target, with many antibiotics, including fluoroquinolones, acting by inhibiting its activity.
Inhibition of DNA gyrase activity, stabilization of cleavage complexes leading to DNA double-strand breaks
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA Gyrase (Topoisomerase II) (DNA Gyrase).